Seegene

Smaller device makers put in a muted performance

Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.

Hope replaces hype for coronavirus stocks

Investors are homing in on biopharma companies able to make real contributions to the coronavirus pandemic, but market frothiness is far from over.

February 27, 2020

Coronavirus stock hype proves infectious

Coronavirus-focused investors have willingly backed bona fide development and egregious publicity stunts alike.

January 15, 2015

Mid-cap medtech shares rise in 2014 on deals and the possibility of more